Sugi absorbent swabs, dacrocystorhinostomy and partial respiratory obstruction

Abstract

CorrespondenceThree aspects are noteworthy. Firstly, doxapram did not reverse the sedation produced by the induction dose of nalbuphine. Secondly, the massive dose of nalbuphine, without subsequent apnoea, confirmed to us its claimed ceiling respiratory depressant effect, a unique safety feature of this drug. Thirdly, the subsequent rousal produced by naloxone indicates that this is the agent of choice in the event of nalbuphine-induced sedation. These latter two safety aspects, combined with the reports of others and our own observations of its analgesic efficacy, have encouraged our continued use of nalbuphine as adjuvant for impatient anaesthesia. Riyadh Armed Forces